CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial.
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (pr
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes…
Medicine Advances is an open access general medical journal with a focus on new technologies, methods and products in the full life cycle of diseases.
The ESMO Academy continues to offer delegates a comprehensive, thorough update on the key topics in medical oncology
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses a survey comparing the use of CAR-T products axicabtagene ciloleucel (axi-cel) and tisagenlecleucel…
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.